Biora Therapeutics, Inc. – NASDAQ:PROG
Biora Therapeutics stock price today
Biora Therapeutics stock price monthly change
Biora Therapeutics stock price quarterly change
Biora Therapeutics stock price yearly change
Biora Therapeutics key metrics
Market Cap | 8.18M |
Enterprise value | 224.07M |
P/E | -0.25 |
EV/Sales | 165.48 |
EV/EBITDA | -1.00 |
Price/Sales | 119.67 |
Price/Book | -1.73 |
PEG ratio | N/A |
EPS | -7.11 |
Revenue | N/A |
EBITDA | -66.83M |
Income | -110.86M |
Revenue Q/Q | 27000% |
Revenue Y/Y | 608% |
Profit margin | -16909.6% |
Oper. margin | -7849.41% |
Gross margin | 92.1% |
EBIT margin | -7849.41% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBiora Therapeutics stock price history
Biora Therapeutics stock forecast
Biora Therapeutics financial statements
| Jun 2023 | 2K | -17.80M | -890350% |
|---|---|---|---|
| Sep 2023 | 0 | -73.45M | |
| Dec 2023 | 872K | -15.41M | -1767.55% |
| Mar 2024 | 542K | -4.18M | -772.88% |
| 2021-08-12 | -0.8 | -0.65 |
|---|---|---|
| 2021-11-10 | -0.47 | -0.38 |
| 2022-03-28 | -0.16 | -0.56 |
| Payout ratio | 0% |
|---|
| 2019 | 0.07% |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 49673000 | 170.55M | 343.35% |
|---|---|---|---|
| Sep 2023 | 34703000 | 153.48M | 442.29% |
| Dec 2023 | 31215000 | 132.63M | 424.91% |
| Mar 2024 | 22990000 | 123.17M | 535.78% |
| Jun 2023 | -11.62M | -19K | 7.63M |
|---|---|---|---|
| Sep 2023 | -11.03M | -1K | -2.84M |
| Dec 2023 | -13.74M | 2.46M | 13.91M |
| Mar 2024 | -12.49M | 3.00M | 5.1M |
Biora Therapeutics alternative data
| Aug 2023 | 124 |
|---|---|
| Sep 2023 | 124 |
| Oct 2023 | 124 |
| Nov 2023 | 124 |
| Dec 2023 | 124 |
| Jan 2024 | 124 |
| Feb 2024 | 124 |
| Mar 2024 | 124 |
| Apr 2024 | 124 |
| May 2024 | 124 |
| Jun 2024 | 124 |
| Jul 2024 | 124 |
Biora Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Aug 2020 | 10000 | 0 |
| Sep 2020 | 9250 | 0 |
| Dec 2020 | 422609817 | 0 |
| Jun 2021 | 33001280 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ATHYRIUM OPPORTUNITIES FUND (A) LP 10 percent owner | Common Stock | 8,097,166 | $2.84 | $22,995,951 | ||
Purchase | ATHYRIUM OPPORTUNITIES FUND (A) LP 10 percent owner | Warrant | 8,097,166 | $2.84 | $22,995,951 | ||
Purchase | ATHYRIUM CAPITAL MANAGEMENT, LP 10 percent owner | Common Stock | 8,097,166 | $2.84 | $22,995,951 | ||
Purchase | ATHYRIUM CAPITAL MANAGEMENT, LP 10 percent owner | Warrant | 8,097,166 | $2.84 | $22,995,951 | ||
Purchase | ATHYRIUM CAPITAL MANAGEMENT, LP 10 percent owner | Common Stock | 306,308 | $2.86 | $876,041 | ||
Purchase | ATHYRIUM OPPORTUNITIES FUND (A) LP 10 percent owner | Common Stock | 306,308 | $2.86 | $876,041 | ||
Purchase | SILVESTRY DAMON officer: Chief Op.. | Common Stock | 58,081 | $4.55 | $264,269 | ||
Purchase | SILVESTRY DAMON officer: Chief Op.. | Common Stock | 58,081 | $4.55 | $264,269 | ||
Purchase | SILVESTRY DAMON officer: Chief Op.. | Common Stock | 63,870 | N/A | N/A | ||
Purchase | ALTER JEFFREY D. director | Common Stock | 20,000 | N/A | N/A |
| Patent |
|---|
Application Filling date: 10 Mar 2022 Issue date: 25 Aug 2022 |
Application Filling date: 19 Jun 2019 Issue date: 18 Aug 2022 |
Application Filling date: 19 Nov 2019 Issue date: 11 Aug 2022 |
Grant Filling date: 19 Apr 2021 Issue date: 17 May 2022 |
Grant Filling date: 4 Aug 2021 Issue date: 10 May 2022 |
Application Filling date: 13 Dec 2018 Issue date: 5 May 2022 |
Application Filling date: 21 Oct 2021 Issue date: 7 Apr 2022 |
Application Filling date: 6 May 2021 Issue date: 7 Apr 2022 |
Application Filling date: 7 Dec 2021 Issue date: 24 Mar 2022 |
Application Filling date: 8 Mar 2021 Issue date: 10 Mar 2022 |
| Quarter | Transcript |
|---|---|
| Q4 2021 28 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 10 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 12 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 13 May 2021 | Q1 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Eric d'Esparbes (1968) Chief Financial Officer | $602,670 |
| Mr. Damon Silvestry (1969) Chief Operating Officer | $461,710 |
-
What's the price of Biora Therapeutics stock today?
One share of Biora Therapeutics stock can currently be purchased for approximately $0.88.
-
When is Biora Therapeutics's next earnings date?
Unfortunately, Biora Therapeutics's (PROG) next earnings date is currently unknown.
-
Does Biora Therapeutics pay dividends?
No, Biora Therapeutics does not pay dividends.
-
How much money does Biora Therapeutics make?
Biora Therapeutics has a market capitalization of 8.18M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 98.69% to 4K US dollars. Biora Therapeutics made a loss 124.12M US dollars in net income (profit) last year or -$0.56 on an earnings per share basis.
-
What is Biora Therapeutics's stock symbol?
Biora Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PROG".
-
What is Biora Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Biora Therapeutics?
Shares of Biora Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Biora Therapeutics's key executives?
Biora Therapeutics's management team includes the following people:
- Mr. Eric d'Esparbes Chief Financial Officer(age: 57, pay: $602,670)
- Mr. Damon Silvestry Chief Operating Officer(age: 56, pay: $461,710)
-
How many employees does Biora Therapeutics have?
As Jul 2024, Biora Therapeutics employs 124 workers.
-
When Biora Therapeutics went public?
Biora Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 19 Jun 2020.
-
What is Biora Therapeutics's official website?
The official website for Biora Therapeutics is progenity.com.
-
Where are Biora Therapeutics's headquarters?
Biora Therapeutics is headquartered at 4330 La Jolla Village Drive, San Diego, CA.
-
How can i contact Biora Therapeutics?
Biora Therapeutics's mailing address is 4330 La Jolla Village Drive, San Diego, CA and company can be reached via phone at +855 2932639.
Biora Therapeutics company profile:
Biora Therapeutics, Inc.
progenity.comNASDAQ
124
Biotechnology
Healthcare
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
San Diego, CA 92122
CIK: 0001580063
ISIN: US74319F1075
CUSIP: 74319F107
